Throat Cancer Global Market Report 2025

The throat cancer market size has grown strongly in recent years. It will grow from $2.25 billion in 2024 to $2.45 billion in 2025 at a compound annual growth rate (CAGR) of 9%. Growth during the historical period was supported by an increase in smoking rates, a surge in alcohol consumption, a rise in HPV infections, greater prevalence of gastroesophageal reflux disease (GERD), and worsening urban air pollution levels.

The throat cancer market size is expected to see strong growth in the next few years. It will grow to $3.42 billion in 2029 at a compound annual growth rate (CAGR) of 8.7%. Projected growth will be driven by increased demand for personalized medicine, broader adoption of tele-oncology and advanced diagnostics, greater use of genetic profiling and biomarkers, rising popularity of vaping and e-cigarettes, and an uptick in obesity and sedentary lifestyles. Key trends anticipated in the forecast period include innovations in treatment approaches, enhanced diagnostic tools using novel technologies, the emergence of new drugs and therapies, use of AI and machine learning for predictive diagnostics, and the digital integration of speech therapy solutions.

The rise in the smoking population is anticipated to drive the growth of the throat cancer market in the coming years. The smoking population refers to the proportion or number of individuals in a specific area who consistently consume tobacco products. This population is increasing due to higher stress levels, prompting more individuals to turn to smoking as a coping strategy. Throat cancer highlights the serious health risks associated with smoking, underscoring the urgent need for public awareness and preventive efforts to reduce its occurrence among smokers. For example, in October 2024, the European Respiratory Society (ERS), a Switzerland-based non-profit organization, reported a significant increase in smoking rates among young people, rising from 22.5% in 2022 to 40.1% in 2024. As a result, the growing smoking population is contributing to the expansion of the throat cancer market.

Leading companies in the throat cancer market are emphasizing the development of innovative therapies, such as immuno-oncology drugs, to improve treatment effectiveness and patient survival rates. Immuno-oncology drugs utilize the body’s immune system to detect and destroy cancer cells, offering a more targeted and efficient treatment approach. For instance, in November 2024, Dr. Reddy's Laboratories Ltd., an India-based pharmaceutical company, launched Toripalimab to treat nasopharyngeal carcinoma, a rare and aggressive type of throat cancer. This innovative therapy leverages immune checkpoint inhibition by targeting the PD-1 receptor, thereby enabling the immune system to better recognize and eliminate cancer cells. Toripalimab provides a new therapeutic option for patients with limited choices, potentially enhancing survival outcomes and quality of life.

In January 2024, Inovio Pharmaceuticals Inc., a US-based biotechnology company, entered into a partnership with Coherus BioSciences to advance DNA-based immunotherapies for cancer. The collaboration aims to accelerate the development of INO-3112 in combination with LOQTORZ to treat HPV-associated cancers more effectively. Through this partnership, the companies seek to improve patient outcomes by utilizing cutting-edge immunotherapy methods. Coherus BioSciences Inc. is a US-based firm specializing in the development and commercialization of immuno-oncology treatments for difficult-to-treat cancers.

Major players in the throat cancer market are Pfizer Inc., Roche Holding AG, Merck and Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Dr. Reddy's Laboratories, Biocon Ltd., Coherus BioSciences Inc., Inovio Pharmaceuticals Inc., Boston Biomedical Inc., Shanghai Sunway Biotech Co. Ltd., and Odon Life Sciences.

North America was the largest region in the throat cancer market in 2024. The regions covered in throat cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the throat cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Throat cancer is characterized by the development of malignant cells within the throat tissues, encompassing areas such as the pharynx, larynx, and tonsils. Common symptoms include a persistent sore throat, hoarseness, and difficulty swallowing. The condition is frequently associated with risk factors like tobacco use, alcohol consumption, and infection with the human papillomavirus (HPV).

There are two primary forms of throat cancer: pharyngeal cancer and laryngeal cancer. Pharyngeal cancer arises in the pharynx - the section of the throat located behind the nose and mouth - and can impact specific regions including the nasopharynx, oropharynx, and hypopharynx. Available treatments range from surgery and radiation therapy to chemotherapy, targeted therapy, antimetabolites, platinum-based drugs, plant-derived treatments, nitrogen mustard agents, antibiotics, and others. These therapies are administered across various end-user settings such as hospitals, multispecialty clinics, cancer research centers, and ambulatory surgical units.

The throat cancer market research report is one of a series of new reports that provides throat cancer market statistics, including the throat cancer industry's global market size, regional shares, competitors with the throat cancer market share, detailed throat cancer market segments, market trends and opportunities, and any further data you may need to thrive in the throat cancer market. This throat cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The throat cancer market consists of revenues earned by entities by providing services such as diagnostic services, immunotherapy services, palliative care services, and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The throat cancer market also includes sales of chemotherapy drugs, radiation therapy equipment, immunotherapy drugs, targeted therapy drugs, and surgical instruments. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.